



**Lonza**

Pharma & Biotech

# the next supply solution...

Let's create it together.

**ibex**<sup>TM</sup>

**dedicate**

As the biopharma industry identifies faster and more efficient ways to deliver drugs to patients, such as break-through and fast track designations for accelerated approval, these progresses create pressure on both large and small drug manufacturers. As development timelines shorten, decisions related to drug commercialization need to be taken earlier, when key results are not yet available. And deciding on the scale and type of facility to build without complete data can create substantial risks with costly consequences.

## **A game-changing supply solution**

To help you navigate through uncertainty, accelerate and de-risk your clinical and commercial program, we have created Ibex™ Dedicate, a fully customizable supply solution.

Based on a modular, technology-agnostic bio-manufacturing concept, Ibex™ Dedicate provides a concept from clinical to commercial for virtually any biologics at any scale, including drug substance and drug product, at one site.

## **The flexibility of a fully customizable supply solution:**

- A dedicated facility which is kept permanently primed for fit-out
- A facility design that can rapidly be scaled with your needs
- A technology-agnostic solution that can be tailored to suit mammalian and microbial production, vaccines, bio-conjugates, and cell and gene therapy
- An offering fitted to your product, from facility design and staffing to the technology, scale, and business and ownership models

## **Speed with increased predictability**

Ibex™ Dedicate can help you save up to 30 months total time to market compared with industry standards:

- A pre-built facility wing can save you 18 months of construction time
- A faster ramp up to full operation enables time savings of up to 12 months

As construction and ramp up times are shorter, you can delay your capacity build decisions without deferring your market entry, and synchronize your investment with your clinical progress.


### Decreased investment risks

The pre-built set-up helps you reduce your CAPEX by up to 25–30% compared to typical large-scale capacity and lower your overall operating costs through shared utilities and infrastructure. The flexible ownership and operating models give you freedom of defining your level of control. For example, we can deploy trained staff or train your staff. We also offer on-site training center to ensure successful start-up and operation on time.

### Agility to address demand unpredictability


Thanks to the agile modular concept, Ibex™ Dedicate manufacturing capacity can grow with your requirements. For example, you can choose a single module to host a small-scale single use production unit and expand when you hit a milestone. Or you could directly opt for several modules to establish your larger scale production unit. At all times, you are able to scale up, down and out, to synchronize production with your clinical or commercial successes.

### Faster to market: save up to 30 months total time to market



### About Ibex™ Solutions

Ibex™ Solutions consist of three CDMO offerings: Ibex™ Design, Ibex™ Develop and Ibex™ Dedicate that span the complete biopharmaceutical lifecycle – from preclinical to commercial stages, from drug substance to drug product, all in one location. The variety of solutions offerings provide the flexibility of a complete program – from gene to drug product, or the option to drop in at a later stage depending where you are in your journey.



Explore how Ibex™ Solutions can help you take your next drug to the market more quickly with game changing business and operating models [www.ibex.lonza.com](http://www.ibex.lonza.com)

### Contact us

USA +1 201 316 9200  
Japan +81 (0)3 6264 0600  
Rest of world +41 61 316 81 11  
Email [ibex@lonza.com](mailto:ibex@lonza.com)

[ibex.lonza.com](http://ibex.lonza.com)



The information contained herein are intended for general marketing purposes only. While Lonza makes efforts to include accurate and up-to-date information, it makes no representations or warranties, express or implied, as to the accuracy or completeness of the information provided herein and disclaim any liability for the use of this publication and that all access and use of the information contained herein are at their own risk. Lonza may change the content of this publication at any time without notice but does not assume any responsibility to update it. All trademarks belong to Lonza or its affiliates or to their respective third party owners and are only being used for informational purposes.

©2019 Lonza. All rights reserved.